측방유동분석법 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Lateral Flow Assays Market Summary

The global lateral flow assays (LFA) market size was estimated at approximately USD 10.17 billion in 2025 and is projected to reach USD 17.44 billion by 2033, growing at a CAGR of 7.41% from 2026 to 2033, driven by the increasing demand for rapid and cost-effective diagnostic solutions, particularly in Point-of-Care (POC) and home-testing applications. Infectious diseases remain one of the main global health challenges.

Infectious diseases remain one of the main global health challenges. In 2025, new infectious disease threats have emerged, further underscoring the need for LFAs. In Louisiana, a fatal case of avian influenza A (H5N1) was reported, linked to inadequate protective equipment among workers handling infected animals. The CDC noted 67 human cases of H5N1 in 2024, with 40 cases tied to dairy cattle exposure and 23 to poultry farms. The UK responded by securing 5 million doses of an H5 vaccine to mitigate risks in 2025. In February 2025, Ireland confirmed its first case of mpox caused by monkeypox clade I, a strain previously dominant in Africa. Simultaneously, Uganda declared an Ebola outbreak in January 2025, with the WHO confirming seven cases, including one fatality, by February. These outbreaks illustrate the unpredictable nature of infectious diseases, driven by global interconnectivity and environmental factors.

The high prevalence of infectious diseases worldwide has been a major driver for the market growth. These diseases necessitate novel diagnostic techniques for efficient treatment to stop the rising mortality rate. The COVID-19 pandemic, in particular, highlighted the need for rapid and accessible diagnostic tools, leading to a surge in demand for LFAs. Beyond COVID-19, other infectious threats have emerged. For instance, in 2025, a highly pathogenic avian influenza A (H5N1) virus infection resulted in a fatality in Louisiana, USA, despite the use of personal protective equipment that was deemed inadequate. According to the Centers for Disease Control and Prevention (CDC), while the general public faces a low risk, individuals working closely with infected animals-such as farmers, veterinarians, and wildlife facility staff-remain highly vulnerable. In 2024, 67 human cases of avian influenza were reported, with 40 linked to exposure to dairy cattle and 23 associated with poultry farms. In response, the UK proactively secured 5 million doses of the H5 vaccine to mitigate potential risks in 2025.

Technological advancements now allow for improved performance and use of lateral flow assays, including advances in sensitivity, specificity, multiplexing, and digital applications via smartphone apps and cloud-connected devices. The latter advances have meant that lateral flow devices may be used in areas outside infectious disease detection, including pregnancy testing, heart disease monitoring, veterinary diagnostics, environmental testing, and food safety. As part of the advances above, Abingdon Health plc (UK) has established itself as a key player in the lateral flow market. In May 2024, Abingdon Health plc launched Boots' own-brand saliva-based pregnancy self-test to the UK and online via Salignostics and Crest Medical. This product represents a technological shift from traditional urine-based pregnancy tests to non-invasive saliva testing, thus providing greater convenience and accessibility for the user. In addition to launching the product, the significant advancement in product innovation provided an opportunity to further strengthen Abingdon Health's strategic partnership with Boots as the first company to adapt a saliva pregnancy self-test into Boots' own-brand range. These advances demonstrate how biotechnology innovation, consumer health, and strategic partnerships continue to influence the direction of the global lateral flow assays industry.

Global Lateral Flow Assays Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lateral flow assays market report based on product, application, technique, end-use, and region:

• Product Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Kits & Reagents
• Lateral Flow Readers
  • Digital/Mobile Readers
  • Benchtop Readers
• Application Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Clinical Testing
  • Infectious Diseases Testing
  • COVID-19 Testing
  • Mosquito Borne Disease Testing
  • Malaria Testing
  • Dengue Testing
  • Zika Testing
  • Chikungunya Testing
  • Others
  • Influenza Testing
  • Sexually Transmitted Infection Testing
  • HIV Testing
  • HPV Testing
  • Chlamydia Testing
  • Gonorrhea Testing
  • Syphilis Testing
  • Others
  • Hepatitis
  • Tuberculosis
  • Others
  • Cardiac Marker Testing
  • Troponin I and T Testing
  • CK-MB Testing
  • BNP and NT-proBNP Testing
  • Myoglobin Testing
  • D-Dimer Testing
  • Others
  • Pregnancy & Fertility Testing
  • Pregnancy Testing
  • Fertility Testing
  • Cholesterol Testing/Lipid Profile Testing
  • Drugs of Abuse Testing
  • Others
• Veterinary Diagnostics
• Food safety & Environment Testing
• Drug Development & Quality Testing
• Technique Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Sandwich Assays
• Competitive Assays
• Multiplex Detection Assays
• End-use Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Home Care
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Lateral Flow Assays market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. Technique Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Lateral Flow Assays Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product Snapshot
• 2.3. Application Snapshot
• 2.4. Technique Snapshot
• 2.5. End Use Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. Lateral Flow Assays Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of infectious diseases
    • 3.3.1.2. Technological advancements in lateral flow
    • 3.3.1.3. Growing adoption in homecare settings
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Stringent Regulations
• 3.4. Porter's Five Forces Analysis
• 3.5. PESTLE Analysis

Chapter 4. Lateral Flow Assays Market: Product Estimates & Trend Analysis

• 4.1. Lateral Flow Assay Market: Product Movement Analysis
• 4.2. Kits & Reagents
  • 4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 4.3. Lateral Flow Readers
  • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 4.3.2. Benchtop Readers
    • 4.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 4.3.3. Digital Readers
    • 4.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 5. Lateral Flow Assays Market: Application Estimates & Trend Analysis

• 5.1. Lateral Flow Assay Market: Application Movement Analysis
• 5.2. Clinical Testing
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.2. Infectious Disease Testing
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.2. COVID-19
      • 5.2.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.3. Mosquito Borne Disease Testing
      • 5.2.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.2. Malaria Testing
        • 5.2.2.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.3. Dengue Testing
        • 5.2.2.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.4. Zika Testing
        • 5.2.2.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.5. Chikungunya Testing
        • 5.2.2.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.6. Others
        • 5.2.2.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.4. Influenza Testing
      • 5.2.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.5. Sexually Transmitted Infection Testing
      • 5.2.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.2. HIV Testing
        • 5.2.2.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.3. HPV Testing
        • 5.2.2.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.4. Chlamydia Testing
        • 5.2.2.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.5. Gonorrhea Testing
        • 5.2.2.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.6. Syphilis Testing
        • 5.2.2.5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.7. Other STI Testing
        • 5.2.2.5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.6. Hepatitis
      • 5.2.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.7. Tuberculosis
      • 5.2.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.8. Other Infectious Diseases
      • 5.2.2.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.3. Cardiac Marker Testing
    • 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.2. Troponin I and T Testing
      • 5.2.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.3. CK-MB Testing
      • 5.2.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.4. BNP and NT-Probnp Testing
      • 5.2.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.5. Myoglobin Testing
      • 5.2.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.6. D-Dimer Testing
      • 5.2.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.7. Other Cardiac Marker Tests
      • 5.2.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.4. Pregnancy & Fertility Testing
    • 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.4.2. Pregnancy Testing
      • 5.2.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.4.3. Fertility Testing
      • 5.2.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.5. Cholesterol Testing/Lipid Profile
    • 5.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.6. Drugs of Abuse Testing
    • 5.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.7. Other Clinical Tests
    • 5.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 5.3. Veterinary Diagnostics
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 5.4. Food Safety & Environment Testing
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 5.5. Drug Development & Quality Testing
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 6. Lateral Flow Assays Market: Technique Estimates & Trend Analysis

• 6.1. Lateral Flow Assay Market: Technique Movement Analysis
• 6.2. Sandwich Assays
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 6.3. Competitive Assays
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 6.4. Multiplex Detection Assays
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 7. Lateral Flow Assays Market: End Use Estimates & Trend Analysis

• 7.1. Lateral Flow Assay Market: End Use Movement Analysis
• 7.2. Hospitals & Clinics
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 7.3. Diagnostic Laboratories
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 7.4. Home Care
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 7.5. Pharmaceutical & Biotechnology Companies
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 7.6. Other End Use
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 8. Lateral Flow Assays Market: Regional Estimates & Trend Analysis

• 8.1. Lateral Flow Assay Market Share, By Region, 2025 & 2033, USD Million
• 8.2. North America
  • 8.2.1. North America Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. U.S. Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Canada Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Mexico Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 8.3. Europe
  • 8.3.1. Europe Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. UK Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Germany Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. France Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Italy Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Spain Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Denmark Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Sweden Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Norway Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Japan Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. China Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. India Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Australia Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. South Korea Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Thailand Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 8.5. Latin America
  • 8.5.1. Latin America Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Brazil Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Argentina Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. South Africa Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Saudi Arabia Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. UAE Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Kuwait Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. Abbott
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Bio-Rad Laboratories, Inc
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Siemens Healthineers AG
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. BIOMERIEUX
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. BD
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. QIAGEN
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. QuidelOrtho Corporation
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. F. Hoffmann-La Roche
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. DH Life Sciences, LLC.
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Quest Diagnostics
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives